The FDA declined to approve Intellipharmaceutics International ‘s long-acting opioid painkiller in its current form.
The U.S. DEA proposed a 20 percent reduction in the manufacture of certain commonly prescribed opioid painkillers as well as other controlled substances for 2018.
July 21, 2017 By Alex Keown, BioSpace.com Breaking News Staff DUBLIN – Less than one month after Endo International (ENDP) agreed to pull its opioid pain medication, the reformulated Opana ER, from the market, the company announced it was shuttering a manufacturing facility in Alabama and terminating hundreds of employees. Endo said the move follows […]
Health insurer Anthem Inc. filed a lawsuit against Insys Therapeutics Inc., alleging the drugmaker fraudulently obtained reimbursements for its opioid painkiller Subsys.
U.S. Attorney General Jeff Sessions will unveil a major crackdown on healthcare fraud involving opioid treatment programs, Bloomberg News reported, citing two people familiar with the matter.
Mallinckrodt Plc, one of the largest manufacturers of the generic opioid painkiller oxycodone, will pay $35 million to resolve allegations that it failed to report suspicious drug orders, the U.S. Justice Department said.
Oklahoma joined growing litigation over claims drugmakers misrepresented the risks of opioid painkillers, as New Hampshire cleared a hurdle in its own probe of the role played by companies in the national addiction epidemic.
Missouri became the third U.S. state to accuse major drug manufacturers of fraudulently misrepresenting the risks of opioid painkillers.